Inozyme Pharma (NASDAQ:INZY) Given Outperform Rating at Wedbush

Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday, Benzinga reports. They presently have a $15.00 target price on the stock. Wedbush’s target price suggests a potential upside of 172.73% from the stock’s current price. Separately, Needham & Company […]

Related Keywords

United States ,Inozyme Pharma ,Inozyme Pharma Inc ,Eventide Asset Management ,Venture Partners Investment Advisor ,Needham Company ,Get Free Report ,Capital Partners ,Springs Capital Management ,Asset Management ,Inozyme Pharma Daily ,Nasdaq Inzy ,Minzy ,Medical ,Reiterated Rating ,Wedbush ,